Payment processing for a peptide business is not a standard e-commerce problem. Suppliers, manufacturers and distributors often handle high-value orders, professional buyers, changing product catalogues and international revenue. A setup built for low-value domestic retail may approve the business at first, then restrict it when transaction values rise, the catalogue changes or a later review identifies peptide-related products.
That pattern is one of the main reasons operators search for peptide payment processing after they have already experienced account reviews, delayed settlements or termination. The business may have processed normally for weeks or months. Then a new product, a larger order or a routine catalogue scan causes the processor to reassess the account.
The answer is not to hide the category or move from one generic processor to another. Stability starts with accurate disclosure, sector-aware onboarding and payment infrastructure structured around the real operating model.
Vellis Peptide Payment Solutions are designed for peptide suppliers, manufacturers and distributors that need a more appropriate route to payment infrastructure. Vellis is an authorized provider that works with underlying acquiring and banking partners. In some instances, Vellis may act as a referral agent. Vellis is not a bank, an acquirer or a direct provider of the underlying infrastructure. Its role is to understand the business, coordinate the partner setup and manage the client relationship from onboarding through ongoing support.
This guide explains why mainstream processors fail peptide companies, how peptide processor termination usually develops, what a stable setup should include and how to prepare payment operations for deposits, repeat clients, catalogue expansion and cross-border growth.
Why payment processing fails for peptide businesses
Mainstream processors are usually designed around familiar merchant profiles. Their automated systems work best when a business sells a stable range of conventional products, processes consistent transaction values and serves customers in a limited number of markets.
Peptide companies often do not fit that model.
A peptide supplier may sell to laboratories, clinics, distributors, research organisations, biotechnology companies or other professional buyers. Order values can be significantly higher than a typical consumer purchase. Transaction frequency may be lower because one wholesale order can represent a large amount of revenue. Product availability can change quickly, and a catalogue may expand as buyer demand shifts.
Generic risk systems do not always assess those facts in context. They may see:
- Product names associated with restricted or closely reviewed categories
- High average transaction values
- Sudden increases in monthly volume
- International card activity
- Long fulfilment periods
- A website catalogue that changes frequently
- Research-use language combined with strong consumer interest
- A small number of transactions representing a large share of revenue
Any one of these factors can trigger a review. When several appear together, an automated system may decide that the merchant sits outside the processor’s preferred risk profile.
This does not necessarily mean the business has high chargebacks or weak operations. It may mean the processor uses blanket product-category exclusions and does not have an underwriting route for peptide businesses.
The initial approval can therefore be misleading. Some processors complete only basic automated checks when the account opens. The detailed catalogue review happens later, after processing has already started. The business integrates the checkout, directs customers to card payments and becomes dependent on the account. When the later review identifies the category, the processor may restrict payments or terminate the relationship.
Payment processing for research compounds needs a different approach. The provider should review the business model, catalogue, customer profile, transaction values and geographic activity before the account is submitted to an underlying partner.
The right question is not, “Can this processor approve us today?”
The right question is, “Has the real business been reviewed and accepted under a structure that matches how we operate?”
A business should never misclassify products, hide website pages or route transactions through an unrelated entity. Those actions can turn a category issue into a serious non-disclosure problem.
Vellis Payment Processing is arranged through underlying partners selected according to the client’s actual operating profile. The aim is to place accurate information in front of the relevant partner at the beginning, rather than waiting for an automated review to discover it later.
The peptide operational profile that mainstream processors miss
Peptide companies are often assessed as conventional online retailers, even though their transaction patterns can be very different.
High-value B2B orders
Laboratories, distributors, clinics and other professional buyers may place bulk orders covering several compounds, concentrations, testing requirements and delivery costs. A high transaction value may therefore be normal rather than suspicious.
If the merchant account was underwritten for small consumer purchases, a legitimate wholesale order can still trigger review. Applications should include realistic average and maximum transaction values from the start.
Lower transaction frequency
A peptide business can generate substantial revenue from a small number of orders. A distributor may buy once per month, while a research organisation may purchase only when a new project begins.
Generic systems can misread this pattern because they expect many smaller payments. Sector-aware underwriting recognises that high-value, low-frequency activity can be normal for peptide B2B payment infrastructure.
Professional customer relationships
B2B buyers often require quotations, invoices, purchase orders, certificates of analysis, batch information and shipping records. These documents strengthen the commercial record when they are retained and connected to the payment.
A stable peptide supplier merchant account should support formal B2B purchasing rather than forcing every order through a consumer checkout process.
Catalogue turnover
Suppliers regularly add compounds, change concentrations, introduce bulk formats or remove unavailable items. Catalogue growth is normal, but material changes can affect underwriting.
The payment setup therefore needs a process for reviewing new products before they begin generating transactions.
Cross-border activity
Many peptide companies source, manufacture, warehouse and sell across several jurisdictions. Cross-border peptide payments may involve international cards, multi-currency invoices, bank transfers, FX conversion, sanctions screening and different billing and shipping countries.
This operating profile is not inherently unstable. It becomes unstable when the infrastructure is built around assumptions that do not match the business.
The setup should reflect the real customer type, order values, catalogue, fulfilment model, currencies and growth plans from the beginning.
The specific compounds that trigger processor reviews
Processors do not assess peptide catalogues as scientists, manufacturers or professional buyers do. Automated systems often scan product names and website language against internal risk rules. A compound can trigger review before the wider business is considered.
Names that commonly receive additional attention include:
- BPC-157
- TB-500
- CJC-1295
- Ipamorelin
- Retatrutide
- Other research compounds with high consumer awareness
The presence of one of these products does not automatically determine eligibility. It does mean the provider is likely to examine how the product is described, who can buy it and whether it was disclosed during onboarding.
BPC-157 payment processing
BPC-157 payment processing can be difficult because the compound is widely discussed online in connection with personal outcomes. A processor may therefore review the complete commercial presentation, including product descriptions, claims, testimonials, blog content, advertising, social media, product bundles and buyer controls.
A research-use statement cannot carry the full compliance burden if the rest of the website suggests a different purpose. Product pages, supporting content and advertising should consistently reflect the stated operating model.
TB-500 payment processing
TB-500 payment processing can create a similar issue. The operator should be ready to explain:
- Who purchases the product
- How it is marketed
- What supports the supply chain
- Which countries are served
- How orders are fulfilled
- Whether the product was disclosed
The strongest response is a complete business file, not a generic disclaimer.
CJC-1295, Ipamorelin and Retatrutide
These compounds may also receive closer review because of consumer interest and the way they are marketed across the wider online market.
Operators should check:
- Whether the intended buyer and use are clear
- Whether claims are controlled
- Whether business and policy information is complete
- Whether supplier and product documents are available
- Whether restricted markets are blocked
- Whether advertising matches the website
- Whether new products have been communicated
Payment processing for research compounds is more stable when catalogue review happens at intake. If an underlying acquiring partner cannot support a product, the business should know before it builds revenue through the account.
This is why an authorized provider peptide setup can be more appropriate than an automated application. Vellis can collect the relevant information and coordinate the review with the underlying partner before processing begins.
The mechanics of processor terminations
Peptide processor termination often follows a common sequence. Understanding that sequence helps operators identify where the risk entered the setup.
Initial acceptance
The business completes an online application and submits basic company, ownership and banking information.
The processor may run automated checks and approve the account quickly. The website might receive only a limited scan. The operator assumes that the entire catalogue has been accepted.
In reality, the account may have passed only the first stage of verification.
Normal processing
The account operates without obvious problems. Payments are accepted, settlements arrive and the business integrates the provider into its website, invoicing and accounting processes.
The company may stop maintaining alternative payment methods because card processing appears stable.
This is the point at which operational dependence develops.
The review trigger
A later event causes the processor to examine the account more closely.
Typical triggers include:
- A large transaction
- Rapid volume growth
- An increase in international payments
- A new compound added to the website
- A product keyword detected during a routine scan
- A customer complaint
- A chargeback
- A change in business ownership
- A request for higher limits
- A change in fulfilment time
- A periodic account review
The processor may request invoices, supplier records, customer information, shipping evidence or product documentation.
Restrictions and reserves
While the review is open, the processor may delay settlements, hold part of the balance, introduce a reserve or block new payments.
This can create a working-capital problem even when the business remains profitable. Inventory, production, testing, payroll and shipping costs continue while access to processed revenue becomes limited.
Termination
If the processor decides that the merchant category falls outside its policy or underlying acquiring arrangement, it may close the account. Funds may remain held for a period to cover refunds and disputes.
The business then has to replace the processor while customers are already trying to pay.
Some causes of termination can be reduced. Accurate onboarding, consistent website language, documented fulfilment and advance communication about changes all help.
Other causes are structural. If a processor does not support peptide businesses, better documents will not change its underlying category policy.
The business should therefore distinguish between:
- A correctable documentation or operational issue
- A provider whose infrastructure was never suitable for the category
For a focused analysis of this pattern, see why peptide businesses get terminated.
The aim is not to convince an unsuitable processor to keep the account open for another month. The aim is to build payment infrastructure through partners that have reviewed and accepted the real business.
The real cost of processor instability
Processor instability affects more than the payments declined on the day an account closes. It creates lost revenue, migration work, customer friction and working-capital pressure.
Lost and delayed revenue
Consider a hypothetical supplier processing $450,000 per month through cards, or about $15,000 per day.
If card processing is unavailable for eight days, approximately $120,000 in expected payment volume is affected. If 60 percent of customers complete a bank transfer or return later, the remaining 40 percent represents $48,000 in delayed or potentially lost revenue.
This is an illustration, not an industry benchmark. Each operator should use its own transaction volume, order value and customer behaviour.
Migration costs
Replacing a processor can require:
- New checkout and gateway integration
- Testing and accounting changes
- Updated invoice instructions
- Customer communication
- Staff training
- Refund and reconciliation changes
- Contract review
The technical invoice is only part of the cost. Finance, operations, sales and customer service teams may lose days dealing with the disruption.
Working-capital pressure
A terminated processor may hold funds to cover potential disputes while the business continues paying for manufacturing, inventory, testing, packaging, warehousing, shipping, payroll and refunds.
A profitable company can still face a cash-flow problem when a material share of revenue is temporarily unavailable.
Customer relationship damage
Wholesale buyers expect clear payment instructions. Repeated changes to card links, beneficiary details or invoice procedures can create doubt and delay procurement approval.
The customer does not see the processor’s internal policy. It sees a supplier whose payment route has become unreliable.
Management distraction
When founders and finance teams are responding to reviews and searching for emergency alternatives, they are not focused on sales, fulfilment or expansion.
The correct comparison is not simply one transaction fee against another. It is the total cost of a properly underwritten setup against the total cost of repeated interruptions, migrations and lost confidence.
What a stable peptide payment processing setup looks like
A stable setup does not mean the business will never receive a question. Underlying partners continue to review transaction activity, catalogue changes and company information.
Stability means the account was structured around the real operation and material changes can be handled through a defined process.
Sector-aware onboarding
The provider should understand the products, customer types, order values, monthly volume, markets, shipping locations, fulfilment time, previous processor history and planned growth before submitting the business.
These questions reduce the chance of a later mismatch between actual activity and the approved profile.
Catalogue review at intake
The complete catalogue should be reviewed before processing begins. Product names, descriptions, intended use, marketing, documentation and geographic controls all matter.
An approval that ignores the catalogue is not a stable approval.
Category-aware processing
The underlying acquiring arrangement should match the category, average ticket size and transaction pattern.
As an authorized provider, Vellis works with underlying acquiring partners to arrange Vellis Card Processing options for the approved profile. Vellis does not directly provide the acquiring infrastructure.
Clear commercial terms
The operator should understand transaction fees, cross-border charges, currency conversion costs, chargeback and refund fees, settlement schedules, reserve terms, monthly costs and contract conditions before launch.
Direct account contact
A named contact can coordinate documentation requests, large orders, volume increases, new markets, catalogue changes, chargebacks, settlement issues and technical problems.
Direct contact does not remove partner requirements. It makes them easier to manage.
Controlled growth and multiple payment routes
The account should begin within the expectations agreed during onboarding. Major launches, wholesale contracts and market expansion should be discussed in advance.
The business may also combine cards, bank transfers, deposits, balance payments and multi-currency accounts according to the order and customer.
For more detail, see payment processing for peptide suppliers.
The goal is not to avoid monitoring. It is to make sure the business was accurately understood before monitoring begins.
Deposit collection and pre-payment for high-value orders
Large peptide orders may require the supplier to commit inventory, production time, testing or packaging before delivery. A deposit can protect the business from beginning expensive work without customer commitment.
However, deposits also create chargeback exposure when the terms are unclear or fulfilment takes longer than the buyer expected.
Tie the deposit to a specific order
Every deposit should relate to a documented commercial agreement.
The file should identify:
- Products
- Quantities
- Specifications
- Total order value
- Deposit amount
- Remaining balance
- Production or fulfilment timeline
- Shipping terms
- Cancellation terms
- Refund terms
- Buyer entity
- Authorised buyer contact
For custom manufacturing or bulk preparation, the agreement should state when work begins and what happens if the customer cancels after costs have been incurred.
Terms should be consistent with the laws and contractual requirements applying to the transaction.
Use formal B2B documentation
For high-value orders, retain:
- Quotation
- Purchase order
- Invoice
- Supply agreement
- Customer approval
- Payment confirmation
- Production updates
- Testing records where relevant
- Shipping documents
- Delivery confirmation
A payment receipt proves that money moved. It does not explain what the customer agreed to buy.
Strong commercial records help prevent misunderstandings and support the business if a dispute occurs.
Choose the method according to the order
Cards can work well for urgent orders and deposits within the approved transaction profile.
Bank transfers may be more suitable for larger wholesale invoices, established accounts or customers with formal procurement procedures.
A practical structure may include:
- Card payment for smaller orders
- Deposit for custom or bulk production
- Bank transfer for the remaining balance
- Payment before dispatch
- Multi-currency collection for international clients
The business should not force a very large order through a card account that was underwritten for much smaller payments.
Do not split transactions to avoid controls
Dividing one payment into several charges solely to stay below a limit can appear to be an attempt to bypass the account’s approved conditions.
If a customer needs to place a larger order, contact Vellis before collecting payment. Vellis can coordinate with the underlying acquiring partner and confirm the appropriate route.
Keep the customer informed
Delays can occur because of production, testing, customs or shipping.
The supplier should communicate:
- What caused the delay
- The revised timeline
- The customer’s options
- The next update date
- The contact responsible
Silence increases the chance of a dispute.
A clear deposit process protects both parties. The customer understands what it is paying for, and the supplier has documented evidence of the order, approval and fulfilment steps.
Recurring billing for wholesale accounts and repeat clients, depending on your platform
Repeat peptide buyers often place similar orders on a regular schedule. Some want monthly replenishment, while others require recurring invoices linked to purchasing cycles.
Recurring billing, depending on your platform, can reduce administrative work. It must still be structured around clear consent, accurate order information and appropriate transaction handling.
Separate repeat purchasing from automated billing
A customer who places a new order every month is a repeat customer. That does not automatically mean the supplier can charge the same payment method without fresh approval.
Recurring billing, depending on your platform, applies when the buyer has agreed to an automated schedule, standing order or stored-payment arrangement.
The distinction matters because the amount, timing and consent requirements may differ.
Document the agreement
Before recurring billing, depending on your platform, is activated, the agreement should explain:
- Billing frequency
- Start date
- Amount or calculation method
- Products covered
- Shipping schedule
- Duration
- Cancellation process
- Price-change process
- Treatment of unavailable products
- Refund terms
The buyer should understand whether the payment remains the same or changes with each order.
Confirm platform support
Recurring billing, depending on your platform, is usually controlled partly by the e-commerce, subscription, invoicing or customer-management system.
The platform may determine:
- When a payment request is sent
- Whether failed payments are retried
- How customer consent is recorded
- How cancellation is processed
- What notifications are sent
- How stored-payment references are used
The business should confirm that both the platform and the payment integration can support the required workflow.
Manage variable wholesale orders
Many B2B relationships do not involve the same amount every month.
A distributor may change quantities. A compound may be temporarily unavailable. Shipping costs may vary. Prices may change.
In those cases, recurring billing, depending on your platform, may work best through an approval-based process:
- Prepare the proposed order.
- Send a quotation or invoice.
- Obtain customer approval.
- Process the authorised amount using the agreed payment route.
- Send confirmation and fulfilment details.
This keeps the process efficient without creating confusion about what was charged.
Maintain current records
Keep records of:
- Customer consent
- Authorised contacts
- Billing details
- Shipping details
- Product schedule
- Price changes
- Cancellation requests
- Failed payments
- Order approvals
- Communications
Recurring billing, depending on your platform, should support the customer relationship, not weaken it.
When the workflow is clear, repeat clients can reorder more efficiently while the business maintains evidence for each commercial transaction.
Multi-currency and cross-border peptide operations
International peptide companies may collect revenue in several currencies and pay manufacturers, suppliers or logistics partners in others. Cross-border peptide payments should therefore be planned before the business enters a new market.
Offer suitable currencies
Professional buyers may prefer to receive invoices or pay in a currency they use internally. Suitable currency options can simplify procurement approval, reduce unnecessary conversion and improve reconciliation.
Through underlying banking partners, Vellis can arrange access to Vellis Multi-Currency Accounts, subject to onboarding and the approved structure. Vellis does not directly provide the underlying account infrastructure.
Plan settlement and supplier payments
The business should understand:
- Which currencies customers can use
- Which currencies can be received or retained
- Which account receives the funds
- When conversion occurs
- What fees apply
- How refunds are handled
- Which currencies suppliers require
A company that receives euros, converts them into US dollars and later converts funds back into euros creates avoidable conversion costs. A multi-currency structure may reduce that problem.
Manage FX deliberately
FX rates reflect live market conditions and may change between quotation and execution.
Operators should review the conversion rate, provider margin, transfer fees, receiving-bank costs, supported currencies and settlement time.
Through underlying partners, Vellis Foreign Exchange can be arranged as part of the cross-border setup.
Document complex international orders
A customer, billing entity and delivery address may be in different countries. When that is legitimate, retain records showing who placed the order, which entity paid, where products were shipped and which contract applied.
Apply geographic controls
Vellis supports businesses globally, excluding OFAC-listed countries. Transactions, customers or locations within applicable OFAC restrictions cannot be supported.
Before entering a new market, confirm that the payment method, currency, shipping destination, order value and legal entity structure fit the approved setup.
For further guidance, see cross-border peptide distribution.
Related operators can also review Vellis Supplements Industry, Vellis Pharmacy Industry and Vellis Healthcare Industry.
Adding new compounds to your catalogue without triggering reviews
Catalogue growth is normal in the peptide industry. New compounds attract demand, professional buyers request different specifications and suppliers update available formats.
The risk comes from changing the approved merchant profile without reviewing the effect on payment processing.
Identify material changes
A change is more likely to require review when it includes:
- A compound not included in the original application
- A product with strong consumer interest
- A different customer type
- New human-use claims
- A new sales channel or country
- A major increase in order value or monthly volume
- A new legal entity, manufacturer or fulfilment partner
- A new repeat-order model
When a change affects information used during underwriting, discuss it before launch.
Prepare a product file
For each material addition, prepare the product name, description, intended buyer and use, manufacturer or supplier details, specifications, supporting documents, packaging image, website page, shipping markets and expected sales volume.
One structured submission is easier to review than a series of explanations after the product has already triggered monitoring.
Review connected marketing
Check category pages, blog articles, FAQs, social media, advertising, email campaigns, testimonials, bundles and metadata. The wider marketing should not contradict the business model presented during onboarding.
Communicate and forecast
Adding the product first and explaining it later can appear to be non-disclosure.
Proactive communication allows Vellis to coordinate the review with the underlying acquiring partner before transactions begin. If the launch is likely to change revenue, average ticket size or international activity, include a reasonable forecast.
Maintain a change log
Track the date proposed, product, documents collected, provider notification, partner response, approval date, expected volume, markets and responsible employee.
A stable peptide payment processing arrangement should support growth. It does not require a static catalogue, but it does require material changes to be managed openly.
Authorized provider vs direct processor vs broker
Peptide businesses should know who performs each role in their payment structure. Provider, processor, acquirer, bank and broker do not mean the same thing.
Direct processor
A direct processor provides processing infrastructure through its own processing or acquiring structure.
Vellis is not a direct processor. The underlying infrastructure is provided by acquiring and banking partners.
Acquirer
An acquirer supports the merchant’s ability to accept card payments and carries specific underwriting, network and monitoring responsibilities.
Vellis is not an acquirer. That role belongs to the relevant underlying partner.
Bank
A bank provides banking services under its own licence and regulatory status.
Vellis is not a bank. Banking infrastructure arranged through Vellis is provided by an underlying banking partner.
Broker
A broker commonly introduces a business to another provider. In a limited brokerage relationship, the merchant may need to manage onboarding and support directly after the introduction.
This can create uncertainty about who owns the relationship when an issue occurs.
Authorized provider
Vellis operates as an authorized provider working with underlying acquiring and banking partners.
Its role can include:
- Understanding the business
- Collecting documents
- Coordinating catalogue review
- Identifying a suitable partner route
- Managing onboarding and implementation
- Providing direct account contact
- Coordinating later changes
In some instances, Vellis may act as a referral agent. The structure depends on the client, service and partner arrangement.
Vellis owns the client relationship end to end, while the appropriately authorised partners provide the underlying infrastructure.
Before accepting a setup, ask who underwrites the account, who provides the infrastructure, who holds funds, who reviews catalogue changes, who approves volume increases and who handles settlement or chargeback questions.
A credible provider should explain the structure without implying that it is a bank or acquirer when those roles belong to partner institutions.
How to prepare for onboarding with Vellis
A complete onboarding file allows Vellis to understand the business and present it accurately to the appropriate underlying partners. The goal is to explain who owns the company, what it sells, who buys from it, how products are fulfilled and what payment activity is expected.
Corporate and ownership documents
Prepare:
- Certificate of incorporation and current company extract
- Registered and trading addresses
- Tax information
- Director, shareholder and beneficial-owner details
- Group structure and related entities
- Current banking information
If several entities are involved, provide a simple diagram showing which entity owns the website, signs customer contracts, receives payments, manufactures or holds inventory and ships orders.
Relevant owners and directors may also need current identification and address verification. Documents should be legible and consistent with the corporate records.
Website, catalogue and product documents
Provide the main website, any additional sales websites and the full product catalogue. The site should contain current product descriptions, prices, customer information, terms and conditions, privacy, refund and shipping policies, contact details and geographic restrictions.
Depending on the operation, supporting documents may include:
- Supplier invoices
- Manufacturing or fulfilment agreements
- Product specifications
- Certificates of analysis
- Batch or quality-control records
- Packaging images
- Warehouse agreements
- Relevant licences
- Import or export records
The purpose is to show how products are sourced, controlled and delivered.
Customer and transaction profile
Explain whether customers are laboratories, research organisations, biotechnology companies, distributors, clinics, healthcare organisations, licensed professionals or other commercial buyers.
Include:
- Main customer countries
- B2B and other sales split
- Average and maximum order values
- Typical fulfilment time
- Repeat-order frequency
- Use of deposits
- Required payment methods and currencies
Provide realistic forecasts for monthly volume, transaction count, card and bank-transfer share, cross-border activity, refunds, chargebacks and expected growth.
Do not understate the figures to make the application appear easier. An account structured for a fraction of the real activity is more likely to be reviewed when normal processing begins.
Previous processor history
Disclose previous providers, processing periods, historical volumes, account closures, reserves, held funds, disputes, rejection history and any corrective action taken.
A previous peptide processor termination does not automatically prevent a new setup. Hiding it creates a larger credibility problem if it is identified during underwriting.
The only hard eligibility exclusion under this brief is the MATCH list. If the company, a related merchant or a relevant owner is on the MATCH list, disclose it immediately. Do not use another entity or concealed ownership structure to bypass the restriction.
Geography and technical requirements
List the countries where the business is registered, products are manufactured or stored, customers are located and orders are shipped. Explain the screening and shipping controls in place.
Vellis supports global operations, excluding OFAC-listed countries.
Also provide details of the e-commerce platform, shopping cart, invoicing system, existing gateway, API or hosted payment-page needs, reporting, accounting integration, fraud controls, stored-payment requirements and repeat-order workflow.
Recurring billing, depending on your platform, should be raised during onboarding so Vellis can confirm how the platform and underlying payment arrangement need to work together.
Questions to ask Vellis
During the consultation, confirm:
- Whether Vellis is acting as an authorized provider or referral agent
- Which underlying partner route is being considered
- Whether the full catalogue has been reviewed
- Which compounds require more documentation
- The submitted monthly volume and maximum transaction value
- Possible reserve and settlement terms
- Supported customer and settlement currencies
- How new compounds and large orders should be communicated
- Who will be the direct account contact
- What technical and migration work is required
A strong onboarding process is the foundation of stable peptide payment processing. The catalogue, expected volumes and international activity should be understood before launch, and material changes should be communicated as the company grows.
Vellis coordinates this process as an authorized provider working with underlying acquiring and banking partners. In some arrangements, Vellis may act as a referral agent. It is not a bank, an acquirer or a direct provider of the underlying infrastructure.
The objective is straightforward: build payment infrastructure around the way the peptide business actually operates and maintain it through clear communication as the company scales.
